Annovis Bio Announces Public Offering to Fund Buntanetap Alzheimer's Trial
Annovis Bio has proposed a public offering of common stock and warrants to raise capital for its Phase 3 Alzheimer's study and general corporate purposes.
Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company focused on neurodegenerative diseases, announced a proposed underwritten public offering of shares of its common stock and accompanying warrants. The offering is aimed at raising funds to support the continued clinical development of buntanetap, its lead drug candidate, particularly in a Phase 3 Alzheimer’s disease study.
The company intends to use the net proceeds from the offering for working capital and general corporate purposes, in addition to funding the Alzheimer’s trial. This move comes as Annovis seeks to advance buntanetap through the clinical pipeline, targeting diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).
Buntanetap, formerly known as posiphen, is an investigational once-daily oral therapy designed to inhibit the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43. The drug operates through a specific RNA-targeting mechanism of action, aiming to address the underlying causes of neurodegeneration. By halting disease progression, Annovis hopes to improve cognitive and motor functions in patients.
The proposed public offering is a critical step for Annovis as it seeks to secure the necessary capital to move buntanetap through late-stage trials. The company is currently in Phase 3 development, and successful completion of the Alzheimer’s study could position buntanetap as a potential treatment option for millions of patients worldwide. The news is significant for investors and the biotech sector, as it underscores the financial demands of drug development and the company’s commitment to advancing its pipeline.
For more details, the full press release is available at https://ibn.fm/1cxGA. Additional information about Annovis Bio can be found at www.annovisbio.com.
The offering is subject to market conditions, and there can be no assurance as to the final terms or completion. Annovis Bio, headquartered in Malvern, Pennsylvania, continues to focus on developing treatments for neurodegenerative diseases, with buntanetap at the forefront of its efforts.